Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis

The Lancet. Diabetes & Endocrinology
Anastassios G PittasEthan M Balk

Abstract

Technosphere inhaled insulin is a non-invasive alternative to subcutaneous injectable insulin for adults with type 1 or 2 diabetes. In this systematic review and meta-analysis of randomised controlled trials, we aimed to establish the efficacy, safety, and patient acceptability of Technosphere inhaled insulin in patients with diabetes. We searched MEDLINE, the Cochrane Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and relevant US regulatory documents for reports of randomised trials published in English up to May 30, 2015, that compared mealtime Technosphere inhaled insulin with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabetes. Two reviewers independently extracted data for outcomes of interest and risk of bias. Endpoints included changes in HbA1c concentration and bodyweight, and safety outcomes, including severe hypoglycaemia and pulmonary toxicity. When three or more studies provided relevant data, we did a meta-analysis for the outcome using a profile-likelihood random-effects model. 13 trials met the inclusion criteria for qualitative systematic review; 12 met the inclusion criteria for quantitative meta-analysis (n=5273; age range 18-80). HbA1c decrea...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Mar 30, 1996·Statistics in Medicine·R J Hardy, S G Thompson
Nov 27, 2002·Diabetes Technology & Therapeutics·Andreas PfütznerSolomon S Steiner
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Nov 22, 2005·Expert Opinion on Drug Delivery·Andreas Pfützner, Thomas Forst
Nov 8, 2006·Annals of Internal Medicine·Lisa CegliaAnastassios G Pittas
Oct 6, 2010·Journal of Diabetes Science and Technology·Elizabeth PotockaRobert A Baughman
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Dec 27, 2012·JAMA : the Journal of the American Medical Association·Sohail M MullaGordon H Guyatt
Apr 16, 2014·Annals of Internal Medicine·Elizabeth SelvinJosef Coresh

❮ Previous
Next ❯

Citations

Sep 6, 2015·The Lancet. Diabetes & Endocrinology·Giuseppe Derosa, Pamela Maffioli
Sep 1, 2016·Postgraduate Medicine·George DaileyViral Shah
Jun 20, 2018·Diabetes Technology & Therapeutics·Halis Kaan AkturkSatish K Garg
Aug 5, 2017·Expert Opinion on Drug Delivery·Kathleen H Ang, Jennifer L Sherr
Oct 1, 2019·American Journal of Therapeutics·Pablo Aschner
Oct 22, 2019·Irish Journal of Medical Science·Maria TomkinsDiarmuid Smith
Apr 21, 2020·Diabetes Technology & Therapeutics·Leah M Wilson, Jessica R Castle
Nov 9, 2018·Frontiers in Endocrinology·Ignazio VecchioMariano Martini
Aug 14, 2020·International Journal of Environmental Research and Public Health·Seán M Cunningham, David A Tanner
Feb 27, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Haiying ChengRoman Perez-Soler
Mar 25, 2021·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Sara M Mensink-BoutLiesbeth Duijts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.